Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott N Gettinger

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Cancer Cytopathology|March 16, 2013
Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinomaGuoping Cai, Rebecca Wong, David Chhieng, et al.
JCO Clinical Cancer Informatics|April 21, 2023
Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)Shing M Lee, Weijia Fan, Aijin Wang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2014
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivoRituparna Das, Rakesh Verma, Mario Sznol, et al.
Cancer Research|May 15, 2012
Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencingAzeet Narayan, Nicholas J Carriero, Scott N Gettinger, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 13, 2013
Programmed death ligand-1 expression in non-small cell lung cancerVamsidhar Velcheti, Kurt A Schalper, Daniel E Carvajal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2013
A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancerKimberly L Johung, Xiaopan Yao, Fangyong Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 27, 2018
Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung CancerScott N Gettinger, Anna Wurtz, Sarah B Goldberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung CancerJon Zugazagoitia, Yuting Liu, Maria Toki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trialMark A Socinski, Thomas E Stinchcombe, Dominic T Moore, et al.
JAMA Oncology|February 21, 2020
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled TrialSalma K Jabbour, Abigail T Berman, Roy H Decker, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Cancer Cytopathology|March 16, 2013
Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinomaGuoping Cai, Rebecca Wong, David Chhieng, et al.
JCO Clinical Cancer Informatics|April 21, 2023
Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)Shing M Lee, Weijia Fan, Aijin Wang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2014
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivoRituparna Das, Rakesh Verma, Mario Sznol, et al.
Cancer Research|May 15, 2012
Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencingAzeet Narayan, Nicholas J Carriero, Scott N Gettinger, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 13, 2013
Programmed death ligand-1 expression in non-small cell lung cancerVamsidhar Velcheti, Kurt A Schalper, Daniel E Carvajal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2013
A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancerKimberly L Johung, Xiaopan Yao, Fangyong Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 27, 2018
Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung CancerScott N Gettinger, Anna Wurtz, Sarah B Goldberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung CancerJon Zugazagoitia, Yuting Liu, Maria Toki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trialMark A Socinski, Thomas E Stinchcombe, Dominic T Moore, et al.
JAMA Oncology|February 21, 2020
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled TrialSalma K Jabbour, Abigail T Berman, Roy H Decker, et al.
Pageof 7